LADENBURG THALMANN FINANCIAL SERVICES INC. - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 134 filers reported holding SAGE THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.

Quarter-by-quarter ownership
LADENBURG THALMANN FINANCIAL SERVICES INC. ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q4 2019$56,000
-27.3%
771
+40.2%
0.00%
-100.0%
Q3 2019$77,000
-78.1%
550
-71.4%
0.00%
-66.7%
Q2 2019$351,000
+457.1%
1,922
+380.5%
0.00%
Q1 2019$63,000
+96.9%
400
+19.8%
0.00%
Q4 2018$32,000
-60.5%
334
-41.2%
0.00%
-100.0%
Q3 2018$81,000
+11.0%
568
+24.0%
0.00%0.0%
Q2 2018$73,0000.0%4580.0%0.00%0.0%
Q1 2018$73,000
+15.9%
458
+19.9%
0.00%0.0%
Q4 2017$63,000
+6200.0%
382
+2022.2%
0.00%
Q3 2017$1,0000.0%18
+63.6%
0.00%
Q2 2017$1,0000.0%110.0%0.00%
Q1 2017$1,0000.0%110.0%0.00%
Q4 2016$1,0000.0%110.0%0.00%
Q3 2016$1,00011
-31.2%
0.00%
Q2 2016$0
-100.0%
160.0%0.00%
Q1 2016$1,000
-50.0%
16
-52.9%
0.00%
Q4 2015$2,000
+100.0%
34
+78.9%
0.00%
Q3 2015$1,0000.0%190.0%0.00%
Q2 2015$1,000190.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q3 2015
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 99,306$14,027,0005.76%
Casdin Capital, LLC 312,000$44,070,0005.36%
Palo Alto Investors LP 840,372$118,703,0004.80%
BB BIOTECH AG 1,071,373$151,331,0004.00%
TRV GP II, LLC 37,362$5,277,0003.10%
Eversept Partners, LP 43,621$6,161,4662.70%
RA Capital Management 350,933$49,569,0002.65%
Eventide Asset Management 494,000$69,778,0002.56%
OAK RIDGE INVESTMENTS LLC 241,099$34,055,0001.88%
SUFFOLK CAPITAL MANAGEMENT LLC 93,000$13,136,0001.87%
View complete list of SAGE THERAPEUTICS INC shareholders